Vigil Neuroscience (NASDAQ:VIGL) mentioned the FDA is permitting a Phase 1 medical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial medical maintain associated to the utmost drug publicity restrict.
Vigil mentioned it expects to start dosing wholesome volunteers for the study in October. It added that the FDA’s most publicity restrict for the study exceeds the expected efficacious dose.
The biotech firm mentioned it deliberate to work with the FDA on addressing the partial medical maintain and anticipated to obtain extra particulars from the company within the subsequent 30 days.
The FDA lifted a partial medical maintain on one other Vigil drug candidate, VGL-101, in March.
Shares of Vigil had been up 8% in after-hours buying and selling on Friday.